ArticleDiscover oncology2026
Intratumoral microbiome evaluated progression and outcome of patients with HBV-associated hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInfection of hepatitis B virus (HBV) is a well-known risk factor for hepatocellular carcinoma (HCC). It is currently unknown whether gut microbiome dysbiosis in HCC tissue affects the assessment of progression and clinical outcome in patients with HBV-associated HCC.
methodsThrough a comparative analysis of 16 S gene fragments and biomarkers in tumor tissues from 40 HBV-associated HCC patients, we gained novel insights into the microbiome characteristics of HBV-associated HCC patients.
resultsLEfSe analysis indicated that Burkholderia cepacia (s), Microcuccus luteus (s) and Microcuccus (g) were dominant in HBV-associated HCC tissues (p < 0.05). 16 S rRNA-positive bacteria were not only localized in HCC cells but also overlapped with some of cells with CD68-, MPO-, α-SMA-, or CD34- positive staining in the tumor tissues. We observed that taxa abundance in HCC tissues was significantly associated with clinicopathological variables, such as tumor size, differentiation, invasion of the liver capsule, lymphovascular invasion, metastasis, pTNM, portal hypertension (PTH), Child-Turcotte-Pugh score, BCLC stage, prognosis (overall survival and progression-free survival), serum levels of α-fetoprotein, albumin, and glucose and personal habits (such as smoking and alcohol intake) of the HBV-associated HCC patients (p < 0.05).
conclusionsThis study demonstrated that microbiome dysbiosis would have a profound effect on the progression and outcome of HBV-associated HCC. B. cepacia (s), M. luteus (s), and Microcuccus (g) would be taxon signatures in HBV-associated HCC tissues and might serve as potential targets for the treatment of patients with HBV-associated HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.